-
1. Alano M.A. et al.: Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics, 107, 519-523, 2001.
-
2. Beck S.L.: Prenatal and postnatal assessment of maneb-exposed CD-1 mice. Reprod. Toxicol., 4, 83-290, 1990.
-
3. Bombardier C. et al.: VIGOR Study Group.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med., 343, 1520-1528, 2000.
-
4. Briggs GG. et al.: Drugs in pregnancy and lactation. A reference guide to fetal and neonatal risk. Lippincott Williams & Wilkins, Philadelphia, 2005.
-
5. Burdan F. et al.: Celosomy is associated with prenatal exposure to cyclo-oxygenase inhibitors. Pharmacol. Res., 53, 287-292, 2006.
-
6. Burdan F. et al.: Congenital ventricular septal defects and prenatal exposure to cyclooxygenase inhibitors. Braz. J. Med. Biol. Res., 39, 925-934, 2006.
-
7. Burdan F. et al.: Immuno-expression of the constitutive and inducible cyclo-oxygenase isoforms in maternal and fetal rat lungs. Ann. Univ. Mariae Curie Sklodowska Med. [Sectio D], 61, 330-334, 2006.
-
8. Burdan F. et al.: Localization of cyclo-oxygenase isoforms in maternal and offspring kidney during pregnancy and lactation. Ann. Univ. Mariae Curie Sklodowska Med. [Sectio D], 61, 326-329, 2006.
-
9. Burdan F. et al.: Prenatal effects of DuP-697 - the irreversible, highly selective cyclo-oxygenase-2 inhibitor. Reprod. Toxicol., 17, 413-419, 2003.
-
10. Burdan F. et al.: Skeletal developmental effects of selective and nonselective cyclo-oxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL.(WI)WUBR rats. Toxicology, 216, 204-223, 2005.